Literature DB >> 31596583

Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.

Thuy Nguyen1, Thomas F Gamage1, Ann M Decker1, Daniel Barrus1, Tiffany L Langston1, Jun-Xu Li2, Brian F Thomas1, Yanan Zhang1.   

Abstract

We previously reported diarylurea derivatives as cannabinoid type-1 receptor (CB1) allosteric modulators, which were effective in attenuating cocaine-seeking behavior. Herein, we extended the structure-activity relationships of PSNCBAM-1 (2) at the central phenyl ring directly connected to the urea moiety. Replacement with a thiophene ring led to 11 with improved or comparable potencies in calcium mobilization, [35S]GTPγS binding, and cAMP assays, whereas substitution with nonaromatic rings led to significant attenuation of the modulatory activity. These compounds had no inverse agonism in [35S]GTPγS binding, a characteristic that is often thought to contribute to adverse psychiatric effects. While 11 had good metabolic stability in rat liver microsomes, it showed modest solubility and blood-brain barrier permeability. Compound 11 showed an insignificant attenuation of cocaine seeking behavior in rats, most likely due to its limited CNS penetration, suggesting that pharmacokinetics and distribution play a role in translating the in vitro efficacy to in vivo behavior.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31596583      PMCID: PMC6953423          DOI: 10.1021/acs.jmedchem.9b01161

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  57 in total

Review 1.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Allosteric modulation of the cannabinoid CB1 receptor.

Authors:  Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2005-08-19       Impact factor: 4.436

4.  The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.

Authors:  Kelly S Sink; Peter J McLaughlin; Jodi Anne T Wood; Cara Brown; Pusheng Fan; V Kiran Vemuri; Yan Peng; Yan Pang; Teresa Olszewska; Teresa Olzewska; Ganesh A Thakur; Alex Makriyannis; Linda A Parker; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

5.  End of the line for cannabinoid receptor 1 as an anti-obesity target?

Authors:  Dan Jones
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

Review 6.  Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.

Authors:  Rachel Dopart; Dai Lu; Aron H Lichtman; Debra A Kendall
Journal:  Drug Metab Rev       Date:  2018-01-21       Impact factor: 4.518

7.  Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.

Authors:  Thuy Nguyen; Nadezhda German; Ann M Decker; Jun-Xu Li; Jenny L Wiley; Brian F Thomas; Terry P Kenakin; Yanan Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-07       Impact factor: 3.641

8.  Galpha-subunits differentially alter the conformation and agonist affinity of kappa-opioid receptors.

Authors:  Feng Yan; Philip D Mosier; Richard B Westkaemper; Bryan L Roth
Journal:  Biochemistry       Date:  2008-01-19       Impact factor: 3.162

9.  Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists.

Authors:  D B Houston; A C Howlett
Journal:  Cell Signal       Date:  1998-10       Impact factor: 4.315

10.  SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.

Authors:  Julio Rosenstock; Priscilla Hollander; Soazig Chevalier; Ali Iranmanesh
Journal:  Diabetes Care       Date:  2008-08-04       Impact factor: 17.152

View more
  4 in total

1.  Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior.

Authors:  Thuy Nguyen; Thomas F Gamage; David B Finlay; Ann M Decker; Tiffany L Langston; Daniel Barrus; Michelle Glass; Jun-Xu Li; Terry P Kenakin; Yanan Zhang
Journal:  J Med Chem       Date:  2021-12-20       Impact factor: 7.446

2.  Neuropeptide B/W receptor 1 peptidomimetic agonists: Structure-activity relationships and plasma stability.

Authors:  Thuy Nguyen; Ann M Decker; Rodney W Snyder; Emma C Tonetti; Thomas F Gamage; Yanan Zhang
Journal:  Eur J Med Chem       Date:  2022-01-21       Impact factor: 6.514

3.  Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.

Authors:  Thuy Nguyen; Thomas F Gamage; Ann M Decker; David B Finlay; Tiffany L Langston; Daniel Barrus; Michelle Glass; Danni L Harris; Yanan Zhang
Journal:  Bioorg Med Chem       Date:  2021-05-12       Impact factor: 3.461

4.  Catalyst-Free Site Selective Hydroxyalkylation of 5-Phenylthiophen-2-amine with α-Trifluoromethyl Ketones through Electrophilic Aromatic Substitution.

Authors:  Valentin Duvauchelle; David Bénimélis; Patrick Meffre; Zohra Benfodda
Journal:  Molecules       Date:  2022-01-29       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.